Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 30;6(4):51.
doi: 10.1186/alzrt276. eCollection 2014.

Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Emilio Merlo Pich  1 , Andreas Jeromin  2 , Giovanni B Frisoni  3 , Derek Hill  4 , Andrew Lockhart  5 , Mark E Schmidt  6 , Martin R Turner  7 , Stefania Mondello  8 , William Z Potter  9
Affiliations
Review

Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Emilio Merlo Pich et al. Alzheimers Res Ther. .

Abstract

This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer's disease. These considerations were generated in a roundtable at a recent Wellcome Trust meeting that included experts from academia and industry. It was agreed that MRI, either structural or functional, could be used as a diagnostic, for assessing worsening of disease status, for monitoring vascular pathology, and for stratifying clinical trial populations. It was agreed also that MRI implementation is in its infancy, requiring more evidence of association with the disease states, test-retest data, better standardization across multiple clinical sites, and application in multimodal approaches which include other imaging technologies, such as positron emission tomography, electroencephalography, and magnetoencephalography.

PubMed Disclaimer

References

    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. - DOI - PMC - PubMed
    1. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. Alzheimer’s Disease Neuroimaging Initiative. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9:e111–e194. doi: 10.1016/j.jalz.2013.05.1769. - DOI - PMC - PubMed
    1. Innovative Medicines Initiative homepage. [ http://www.imi.europa.eu/content/pharma-cog]
    1. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther. 2013;5:48. doi: 10.1186/alzrt213. - DOI - PMC - PubMed
    1. Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C. ISTAART’s NeuroImaging Professional Interest Area. Imaging markers for Alzheimer disease: which vs how. Neurology. 2013;81:487–500. doi: 10.1212/WNL.0b013e31829d86e8. - DOI - PMC - PubMed

LinkOut - more resources